Cargando…
Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms
Histiocytoses are clonal hematopoietic disorders frequently driven by mutations in BRAF and MEK1/2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. Here we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898787/ https://www.ncbi.nlm.nih.gov/pubmed/31768065 http://dx.doi.org/10.1038/s41591-019-0653-6 |
_version_ | 1783477026722676736 |
---|---|
author | Durham, Benjamin H. Rodrigo, Estibaliz Lopez Picarsic, Jennifer Abramson, David Rotemberg, Veronica De Munck, Steven Pannecoucke, Erwin Lu, Sydney X. Pastore, Alessandro Yoshimi, Akihide Mandelker, Diana Ceyhan-Birsoy, Ozge Ulaner, Gary A. Walsh, Michael Yabe, Mariko Petrova-Drus, Kseniya Arcila, Maria E. Ladanyi, Marc Solit, David B. Berger, Michael F. Hyman, David M. Lacouture, Mario E. Erickson, Caroline Saganty, Ruth Ki, Michelle Dunkel, Ira J. López, Vicente Santa-María Mora, Jaume Haroche, Julien Emile, Jean-Francois Decaux, Olivier Geissmann, Frederic Savvides, Savvas N. Drilon, Alexander Diamond, Eli L. Abdel-Wahab, Omar |
author_facet | Durham, Benjamin H. Rodrigo, Estibaliz Lopez Picarsic, Jennifer Abramson, David Rotemberg, Veronica De Munck, Steven Pannecoucke, Erwin Lu, Sydney X. Pastore, Alessandro Yoshimi, Akihide Mandelker, Diana Ceyhan-Birsoy, Ozge Ulaner, Gary A. Walsh, Michael Yabe, Mariko Petrova-Drus, Kseniya Arcila, Maria E. Ladanyi, Marc Solit, David B. Berger, Michael F. Hyman, David M. Lacouture, Mario E. Erickson, Caroline Saganty, Ruth Ki, Michelle Dunkel, Ira J. López, Vicente Santa-María Mora, Jaume Haroche, Julien Emile, Jean-Francois Decaux, Olivier Geissmann, Frederic Savvides, Savvas N. Drilon, Alexander Diamond, Eli L. Abdel-Wahab, Omar |
author_sort | Durham, Benjamin H. |
collection | PubMed |
description | Histiocytoses are clonal hematopoietic disorders frequently driven by mutations in BRAF and MEK1/2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. Here we uncover activating mutations in CSF-1R, as well as rearrangements in RET and ALK which confer dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in histiocytosis patients. |
format | Online Article Text |
id | pubmed-6898787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-68987872020-05-25 Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms Durham, Benjamin H. Rodrigo, Estibaliz Lopez Picarsic, Jennifer Abramson, David Rotemberg, Veronica De Munck, Steven Pannecoucke, Erwin Lu, Sydney X. Pastore, Alessandro Yoshimi, Akihide Mandelker, Diana Ceyhan-Birsoy, Ozge Ulaner, Gary A. Walsh, Michael Yabe, Mariko Petrova-Drus, Kseniya Arcila, Maria E. Ladanyi, Marc Solit, David B. Berger, Michael F. Hyman, David M. Lacouture, Mario E. Erickson, Caroline Saganty, Ruth Ki, Michelle Dunkel, Ira J. López, Vicente Santa-María Mora, Jaume Haroche, Julien Emile, Jean-Francois Decaux, Olivier Geissmann, Frederic Savvides, Savvas N. Drilon, Alexander Diamond, Eli L. Abdel-Wahab, Omar Nat Med Article Histiocytoses are clonal hematopoietic disorders frequently driven by mutations in BRAF and MEK1/2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. Here we uncover activating mutations in CSF-1R, as well as rearrangements in RET and ALK which confer dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in histiocytosis patients. 2019-11-25 2019-12 /pmc/articles/PMC6898787/ /pubmed/31768065 http://dx.doi.org/10.1038/s41591-019-0653-6 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Durham, Benjamin H. Rodrigo, Estibaliz Lopez Picarsic, Jennifer Abramson, David Rotemberg, Veronica De Munck, Steven Pannecoucke, Erwin Lu, Sydney X. Pastore, Alessandro Yoshimi, Akihide Mandelker, Diana Ceyhan-Birsoy, Ozge Ulaner, Gary A. Walsh, Michael Yabe, Mariko Petrova-Drus, Kseniya Arcila, Maria E. Ladanyi, Marc Solit, David B. Berger, Michael F. Hyman, David M. Lacouture, Mario E. Erickson, Caroline Saganty, Ruth Ki, Michelle Dunkel, Ira J. López, Vicente Santa-María Mora, Jaume Haroche, Julien Emile, Jean-Francois Decaux, Olivier Geissmann, Frederic Savvides, Savvas N. Drilon, Alexander Diamond, Eli L. Abdel-Wahab, Omar Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title | Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title_full | Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title_fullStr | Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title_full_unstemmed | Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title_short | Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms |
title_sort | activating mutations in csf-1r and additional receptor tyrosine kinases in histiocytic neoplasms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898787/ https://www.ncbi.nlm.nih.gov/pubmed/31768065 http://dx.doi.org/10.1038/s41591-019-0653-6 |
work_keys_str_mv | AT durhambenjaminh activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT rodrigoestibalizlopez activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT picarsicjennifer activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT abramsondavid activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT rotembergveronica activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT demuncksteven activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT pannecouckeerwin activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT lusydneyx activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT pastorealessandro activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT yoshimiakihide activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT mandelkerdiana activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT ceyhanbirsoyozge activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT ulanergarya activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT walshmichael activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT yabemariko activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT petrovadruskseniya activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT arcilamariae activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT ladanyimarc activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT solitdavidb activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT bergermichaelf activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT hymandavidm activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT lacouturemarioe activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT ericksoncaroline activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT sagantyruth activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT kimichelle activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT dunkeliraj activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT lopezvicentesantamaria activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT morajaume activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT harochejulien activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT emilejeanfrancois activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT decauxolivier activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT geissmannfrederic activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT savvidessavvasn activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT drilonalexander activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT diamondelil activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms AT abdelwahabomar activatingmutationsincsf1randadditionalreceptortyrosinekinasesinhistiocyticneoplasms |